Antibody-drug conjugates (ADCs) represent an innovative therapeutic approach that provides novel treatment options and hope for patients with cancer. By coupling monoclonal antibodies (mAbs) to cytotoxic small-molecule payloads with a plasma-stable linker, ADCs offer the potential for increased drug specificity and fewer off-target effects than systemic chemotherapy. As evidence for the potential of these therapies, many new ADCs are in various stages of clinical development. Because their structure poses unique challenges to pharmacokinetic and pharmacodynamic characterization, it is critical to recognize the differences between ADCs and conventional chemotherapy in the design of ADC clinical development strategies. Although some properties may be determined mainly by either the mAb or the small-molecule portion, the behavior of these agents is not always predictable. Furthermore, because the absorption, distribution, metabolism, and excretion (ADME) of ADCs are influenced by all 3 of its components (mAb, linker, and payload), it is important to characterize the intact molecule, any target-mediated catabolic clearance of the mAb, and the ADME properties of the small-molecule payload. Here we describe key issues in the clinical development of ADCs, including considerations for designing first-in-human studies for ADCs. We discuss some difficulties of ADC pharmacokinetic characterization and current approaches to overcoming these challenges. Finally, we consider all aspects of clinical pharmacology assessment required during drug development, using examples from the literature to illustrate the discussion.
Antibody-drug conjugates (ADCs) are a unique class of therapeutic agents that have been under development for several decades, primarily for cancer and recently for other, difficult-to-treat diseases. ADCs are composed of 3 main components: a monoclonal antibody (mAb) that targets a specific antigen; a cytotoxic chemotherapeutic agent or payload, often a small molecule, that is released within target cells; and a chemical linker that bridges the mAb to the payload ( Figure 1a ). The goals of ADCs are to efficiently eliminate cells expressing target antigens and decrease systemic payload exposure, thereby optimizing its benefit:risk profile.
ADC specificity depends on mAb binding to unique antigen targets expressed more highly on target cells than on healthy tissue. Once bound, cells internalize the ADC primarily via receptor-mediated endocytosis, forming an ADC-containing endosome that ultimately is trafficked to a lysosome 1, 2 (Figure 1b) . Within the lysosome, the payload is released by enzymatic digestion and exerts its pharmacological effect. In addition to payload cytotoxicity within target cells, some ADCs have inherent effector functions including antibodydependent cellular cytotoxicity (ADCC), complementdependent cytotoxicity (CDC), and bystander effects that occur if the payload exerts its cytotoxic effect on neighboring antigen-negative cells. [2] [3] [4] Although effector functions may improve ADC antitumor activity, they may adversely affect toxicity if adjacent healthy cells are killed. Healthy cells are also damaged if nonspecific ADC uptake occurs via antigenindependent pinocytosis, uptake of ADC catabolites, or Fc receptor-mediated uptake. 5, 6 Furthermore, ADCs can be recycled by the neonatal Fc receptor (FcRn) after internalization, potentially prolonging systemic exposure by diverting the ADC from lysosomal degradation. Unstable linkers resulting in payload release outside target cells could lead to off-target toxicity. Like mAbs, ADCs have the potential for immunogenicity Figure 1 . Antibody-drug conjugate (ADC) structure and mechanism of action. ADCs consist of a mAb, a cytotoxic drug payload, and a linker that connects the mAb to the payload (a). The mAb binds to cell-surface antigens expressed on target cells, is internalized via endocytosis, and is transported to the lysosome, where proteases degrade the ADC. The payload is then released and diffuses into the cytoplasm, resulting in cell death (b).
and accompanying hypersensitivity, toxicity, increased clearance, or a neutralizing effect. 7 As a complex therapeutic molecule composed of both a mAb and payload, the final ADC drug product can be a heterogeneous mixture with different payload amounts linked to each antibody molecule. This drugto-antibody ratio (DAR) influences ADC efficacy and disposition 8 and is an important aspect factored into ADC design and optimization. The range of DARs for ADCs varies, with a maximum of 8 payload molecules per mAb with current technologies. Future ADCs may achieve lower DAR with improved drug-linker chemistry.
ADCs are an evolving class of therapeutic molecules with many conjugates currently in clinical development. [9] [10] [11] Only 3 ADCs have been approved by the US Food and Drug Administration (FDA), with 2 still on the US market in 2017. In 2000 gemtuzumab ozogamicin (Mylotarg) was the first ADC to gain marketing approval for use in relapsed acute myeloid leukemia 12 and is composed of a humanized antibody to CD33 immunoglobulin G4 conjugated to the DNA-cleaving cytotoxic calicheamicin via a cleavable acid-labile linker. This agent was removed from the market in 2010 because of lack of sufficient efficacy and safety in a confirmatory trial. 13 In 2011 brentuximab vedotin (Adcetris), a CD30-targeting chimeric IgG1 linked to the monomethyl auristatin E (MMAE) antitubulin payload via protease-cleavable dipeptide linker, gained FDA approval for treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Further study of brentuximab vedotin in other types of CD30-expressing lymphomas is ongoing. The ADC ado-trastuzumab emtansine (T-DM1; Kadcyla) was approved by the FDA in 2013 for use in patients with HER2-positive metastatic breast cancer and was the first ADC approved for a solid-tumor indication. Ado-trastuzumab emtansine is composed of the humanized IgG1 mAb trastuzumab (Herceptin) linked to the antitubulin maytansinoid DM1 via a noncleavable thioether linker. Ado-trastuzumab emtansine is currently under evaluation in other HER2-positive cancers.
The goal of this review is to consider ADC drug development from a clinical pharmacologist's perspective and highlight areas requiring further exploration and development. Compared with other classes of therapeutic agents, ADCs pose unique challenges in pharmacokinetic (PK) and pharmacodynamic (PD) characterization. Although some properties are determined mainly by either mAb or payload, the behavior of these agents is not always predictable. We look first at key issues in ADC clinical development, focusing on phase 1 studies. We then consider aspects of clinical pharmacology assessment required during drug development, using examples from the literature.
Clinical Development Strategies of ADCs in Oncology
Selection of Indication and Target Antigen There are 2 approaches to pairing ADCs with indications: (1) first select a target antigen, then choose an indication where it is differentially expressed; or (2) choose an indication first, then identify a target antigen. ADC indication selection is primarily driven by target antigen availability and biological characteristics. 8, 11, 14 To minimize toxicity, target antigens should be predominantly or exclusively expressed on the surface of tumor cells relative to healthy tissue. High antigen expression should increase ADC distribution to the tumor, thereby maximizing therapeutic efficacy; the level of target expression required for effective ADC activity varies with each antigen and chemotype. In addition, the prevalence of target antigen expression (ie, proportion of patients whose tumors express antigen compared with all patients within an indication) impacts the proportion of patients benefiting from therapy; antigens with high expression but low penetrance are unlikely to satisfy the unmet medical need of a majority of patients in an indication.
Phases 1, 2, and 3 Strategies
The broad aims and clinical pharmacology strategies for each phase of clinical development are summarized in Figure 2 . 11 The objectives of oncology phase 1 trials are typically to determine the safety and tolerability of a therapeutic agent, such as the dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), and the PK for exposure-response (E-R) analyses. Often, antitumor activity is also explored in a phase 1 study. Ultimately, a recommended dose and a schedule for further clinical development must be identified. Currently approved ADCs were investigated in typical phase 2 and phase 3 oncology studies where high unmet medical need was evident, using standard efficacy (and safety) end points including objective response rate (ORR), duration of response, progression-free survival (PFS), and overall survival (OS). [15] [16] [17] [18] First-in-Human Study Design First-in-human (FIH) phase 1 study design is critical for success in later stages of clinical development. Key elements include selecting an appropriate patient population, starting dose and schedule, and dose-escalation strategy. In addition, dose-expansion cohorts often explore alternative doses/schedules and indications. It is also helpful to think about the type of toxicity expected and to educate relevant health care professionals and patients to enable prompt identification and intervention as necessary. The inclusion of preliminary PK/PD assessments requires appropriate assays to measure ADC analytes and biomarkers of response.
Selection of Indications and Patient Populations
Oncology phase 1 studies using nonspecific cytotoxic agents typically enroll patients with a broad range of tumor types. However, ADC phase 1 populations may be highly selective if the target antigen is limited to one tumor type or may be broad if the target is expressed on several tumor types. For example, the population for ado-trastuzumab emtansine phase 1 dose escalation consisted of patients with HER2-positive metastatic breast cancer previously treated with a trastuzumabbased regimen, 19 whereas the brentuximab vedotin FIH phase 1 study enrolled patients with relapsed or refractory CD30-positive hematologic cancers. 17 Diagnostic assays are often required to select patients for further ADC evaluation in dose-expansion cohorts, especially if antigen prevalence is low.
Starting Dose and Dose-Escalation Strategies
Like other therapeutics, starting doses for FIH studies of ADCs are based on preclinical efficacy, toxicology, and PK/PD data. Previous ADC investigational drug applications suggest the best balance between safety and efficient dose escalation was achieved with starting doses based on either one-sixth of the highest nonseverely toxic dose in monkeys or one-tenth of the severely toxic dose in 10% of rodents, scaled by body surface area. 20 As with other oncology agents, ADC dose escalation is guided by the incidence of DLTs. 21 ADC dose-escalation algorithms have commonly used a modified Fibonacci sequence, continuous reassessment model, or a 3+3 design with or without accelerated titration, with a median number of 6 dose levels needed to reach the MTD or maximum administered dose. 22 ADC dosing may be based on body surface area (common with small molecules), body weight (typical with large molecules including mAbs), or a flat dose. Dosing for ado-trastuzumab emtansine, brentuximab vedotin, and other developmental ADCs is based on body weight. 17, 19, 22 However, as body size explains only part of the interpatient PK variability for mAbs 23, 24 and ADC PK properties are mostly determined by its mAb portion, 25 flat dosing may be a rational, practical approach for some ADCs.
A theoretical approach for ADC dosing was published that used predosing with naked antibody, followed by a dose of intact ADC. 26, 27 The rationale behind this method was to saturate normal tissue sinks with naked antibody, thereby potentially decreasing off-target toxicity and allowing deeper ADC penetration into tumor tissues. Although there are merits to this approach and it is used for approved radioimmunotherapies, 28, 29 only preclinical examples exist in the ADC space. Successful integration of this methodology in clinical ADC dosing will require careful titration of the naked antibody dose to the intact ADC dose; ratios may have to be patient specific to factor in disease burden and may be dependent on tumor type. Regardless, this approach warrants further investigation. 
Regimens
The ideal dosing regimen optimizes efficacy with minimal or manageable adverse events, but regimens must be practical and conform to accepted standards of care. For most ADCs, dosing once every 3 weeks has been investigated in phase 1 trials. 16, 18, 22, 30 Given the duration of action and relatively short elimination half-life of ADCs compared with mAbs (median approximately 2.3 days; range, 0.71 to 6.90 days), this decision seems a pragmatic one, accounting for safety and efficacy end points and ease of combination with other oncology agents, the majority of which use an every-3-weeks schedule. 22 However, some ADCs have much longer half-lives; rovalpituzumab tesirine has a half-life between 10 and 14 days and is administered every 6 weeks. 31 
Anticipated Toxicities
Anticipating ADC-related toxicity is complicated by unclear links between preclinical and clinical toxicity, and currently available data suggest toxicity is often unrelated to tissue expression of the antigen. 9 For example, despite HER2 expression in the heart, skin, and gastrointestinal epithelia, ado-trastuzumab emtansine shows no significant toxicity in these tissues and has a DLT of reversible thrombocytopenia (considered offtarget). Similarly, ocular toxicity has not been reported for mucin 16 ADC conjugated with vcMMAE (MMAE linked via valine-citrulline dipeptide), although human ocular surface epithelia express mucin 16 antigen. In contrast, one of the DLTs for glembatumumab vedotin was skin rash, probably associated with expression of glycoprotein nonmetastatic b on epithelial cells of the skin. Prior clinical data with a particular cytotoxic payload may be the best, although not always certain, guide to the safety profile of a new ADC. 9 Most ADCs conjugated with vcMMAE have similar toxicity profiles and DLTs of acute neutropenia and peripheral neuropathy, regardless of the antigen targeted, and various disulfide-linked maytansinoid DM4-conjugated mAbs have reversible ocular DLTs, despite lacking significant antigen expression in the eye.
Biomarker Selection
Strategies aim to find biomarkers that are predictive of response or toxicity and can differentiate patients likely to benefit from treatment. For ADCs, potential biomarkers have tumor-cell-surface expression, although receptor/cell density may also be important. Among patients treated with ado-trastuzumab emtansine in the EMILIA and TH3RESA phase 3 studies, those with tumors expressing HER2 above the median level derived the greatest benefit with respect to PFS (both studies) and OS (EMILIA only), although patients with lower HER2 expression benefited from ado-trastuzumab emtansine when compared with chemotherapy. 32, 33 Ado-trastuzumab emtansine is indicated only for patients with HER2-positive metastatic breast cancer. As yet, no other validated biomarkers exist for any ADC. However, ADC phase 1 studies should explore the relationship between tumor target antigen expression and response, as well as the impact of circulating biomarkers on ADC PK. High concentrations of soluble cell-surface antigen in blood may bind and prevent ADCs from reaching tumors, resulting in target-mediated drug disposition (TMDD) and nonlinear PK, making dose selection challenging for phase 2/3 development.
Absorption, Distribution, Metabolism, and Excretion Principles of ADCs
Characterization and Interpretation of ADC PK and Bioanalytical Assays Absorption, distribution, metabolism, and excretion (ADME) are influenced by all components of an ADC, so it is important to characterize the disposition properties of the intact molecule as well as the mAb and payload. In addition to the main analytes of an ADC, the resulting in vivo heterogeneity of molecular species with varying DARs adds complexity to understanding their ADME properties. 34 No standard approach can be applied to all ADCs. The PK of an ADC is primarily driven by the carrier mAb backbone, 25, 35 but the linker, payload, and DAR also impact ADC stability and PK. [36] [37] [38] For example, the hydrophobicity of the linkers conjugated to an anti-CD70 mAb impacted ADC clearance, half-life, and area under the concentration-time curve. 38 In addition, both distribution and elimination phases changed with linker hydrophobicity, indicating an overall change in ADC disposition. 38 Limited in vitro assays contribute to the challenges of ADC PK characterization (recently reviewed 35 ). For instance, validated in vitro assays used to evaluate the ADME of traditional small-molecule therapeutics are not necessarily relevant to large antibody-based therapeutics. 25 Although linker stability can be assessed from in vitro plasma stability assays, ADC catabolite profiles cannot be reliably assessed in isolated tumor cell systems, and in vitro assays designed to investigate ADC uptake by organs such as the liver or lung may be limited because of a lack of target expression. However, in vivo studies used to assess ADCs in these organs are also limited, as the PK of ADCs can be species dependent. 39 Notwithstanding the complexities discussed above, the accepted consensus based on previous ADC experience is that the most useful parameters and information about E-R relationships can be derived by analysis of the ADC, total antibody, and/or unconjugated payload. 25, 37 However, total antibody is typically analyzed in early clinical trials (for example, FIH) and subsequently dropped in later clinical studies because of strong correlation with ADC. Bioanalytical methods, including enzyme-linked immunosorbent assays and liquid chromatography-mass spectrometry, allowed for reliable insights into linker stability, TMDD, and E-R relationships. 37, 40 In vivo ADC biodistribution is assessed during clinical trials using singlephoton emission computed tomography and positron emission tomography imaging. 41 DAR-sensitive or DAR-insensitive bioanalytical methods can be developed and need to be considered depending on the question being addressed.
14 As more in vitro and in vivo PK data become available for ADCs, bioinformatic PK/PD model optimization will provide in silico options for understanding ADCs.
Disposition and Metabolic Fate of ADCs
Because ADCs are continually exposed to plasma proteases, a gradual release of payload with accompanying adverse events may occur. 20 Understanding the mechanism and extent of payload release while an ADC is in circulation is therefore critical when engineering an ADC for systemic stability. In preclinical trials, antigen expression and receptor/cell density impact ADC disposition in addition to factors that impact antibody catabolism, such as FcRn-mediated recycling, Fc-gamma interactions, and receptor-mediated endocytosis. 42 Similar to mAbs, ADC tissue distribution is limited by slow diffusion across vascular endothelial cells and through the lymphatic system following intravenous infusion. ADCs tend to have shorter half-lives compared with their unconjugated parent mAb, in part because conjugation impacts catabolism in a linker-dependent manner. 42 For example, brentuximab vedotin has a serum half-life of 4 to 6 days, yet unconjugated SGN-30 mAb has a halflife of 1 to 3 weeks. 17, 43 The chemical properties of drug linkers also impact ADC stability, as disulfidelinked T-SPP-DM1 cleared approximately 2-fold faster in mice than thioether-linked ado-trastuzumab emtansine, despite comparable clearance of the respective total antibodies. 44 Increased DAR can also shorten serum half-life, suggesting the number of payloads may also influence catabolism. 36 
Clinical Pharmacology and Pharmacometric Strategies for ADC Development
Understanding ADC clinical pharmacology properties begins with predictions based on preclinical PK/PD models, followed by characterization of initial human PK/PD during phase 1. Further study of clinical pharmacology properties for ADCs is then spread across the clinical development program (Figure 2) . 11 Data from 3 approved ADCs provide a reference point for new ADCs.
Organ Dysfunction Studies
In patients with cancer, both the disease and prior non-ADC therapeutic agents may lead to renal or hepatic dysfunction. Because the liver and kidneys are responsible for metabolism and elimination of ADCs, their impairment may result in decreased ADC and/or toxin clearance, leading to higher exposure and potentially increased toxicity. The MTD/maximum administered dose is generally selected for ADC clinical development in patients with cancer, 16, 18, 22, 45 so preexisting organ dysfunction may result in higher exposure and cause deleterious toxicity, precluding further administration and limiting potential therapeutic benefit. Therefore, understanding how organ dysfunction impacts the disposition and safety of ADCs is important to developing appropriate dosing recommendations for patients.
The mAb portion of an ADC is likely eliminated by proteolytic degradation (ie, catabolism) into amino acids, which can be recycled into new proteins or serve as a cellular carbon source. 22, 46 Antibodies cannot undergo glomerular filtration and are generally not catabolized by the liver, so payload elimination route should guide specific ADC renal or hepatic impairment assessments. Alternatively, population PK analysis can investigate the effect of organ impairment; this approach was used to assess the impact of renal impairment on ado-trastuzumab emtansine elimination (Table  1) .
11,47
QTc Strategy A review of QT/QTc study reports for 15 therapeutic biotechnology developmental products (13 mAbs, 2 ADCs) suggests mAbs are unlikely to cause QT/QTc interval prolongation. 48 The low concentrations of circulating payload after ADC dosing would also be unlikely to block cardiac channels. The effect of brentuximab vedotin 49 and ado-trastuzumab emtansine 50 on QT interval was evaluated in dedicated phase 1 and phase 2 studies, respectively; no clinically relevant impact on ventricular repolarization was observed. In the case of ado-trastuzumab emtansine, a novel strategy assessed the effects of conjugate, total trastuzumab (conjugated and unconjugated trastuzumab), and DM1 concentrations on QT interval; the concentration-QT relationship was analyzed using a nonlinear mixedeffects model. 50 In this study, ado-trastuzumab emtansine had no clinically relevant effect on QTc interval. However, because experience with the effect of ADCs on electrophysiology is limited, quantitative electrocardiogram (ECG) monitoring may be warranted in specific cases.
For ADCs using novel but stable payload linkers for which preclinical data suggest no effect on cardiac electrophysiology (eg, negative hERG test and no effect in telemeterized animals), limited ECG evaluation at peak ADC and payload concentrations following the first ADC dose and at steady state should suffice. For ADCs targeting heart tissue with evidence of cardiac effects from preclinical studies or with circulating payload concentrations (eg, because of linker instability), intensive ECG monitoring at multiple points after the first ADC dose and at steady state may be warranted. No additional ECG monitoring is warranted for ADCs including payloads with no known ECG effects or with circulating concentrations similar to or below those established as having no ECG effect.
Overall, QTc liability for ADCs is considered minimal given the mAb component of the ADC and low levels of circulating payloads. Although dedicated QTc clinical studies were conducted for brentuximab vedotin and ado-trastuzumab emtansine, the regulatory landscape has evolved over the past few years following the approval of these agents. Thorough QT or dedicated QT studies may not necessarily be needed for ADCs; intensive ECG monitoring and exposure-QTc analysis in a phase 1 study can be leveraged to assess overall risk and may meet regulatory submission requirements.
Drug-Drug Interaction Assessment
Potential drug-drug interactions (DDIs) exist at both the mAb and payload levels for ADCs. The oftennarrow therapeutic range of ADCs means DDIs resulting in small molecule exposure increases may lead to increased toxicity and impact patient safety.
9,51 The FDA and European Medicines Agency (EMA) have issued comprehensive recommendations for in vitro and in vivo studies to evaluate DDI potential during drug development. 51, 52 Most clinical evaluations appropriately focus on DDIs related to the payload. After release from the ADC, the payload may be metabolized by cytochrome P450 (CYP450) and/or UDP glucuronosyltransferase enzymes and is at risk of DDIs with any coadministered inducers or inhibitors of these systems. However, the low circulating concentrations of payload reduces the potential for DDIs. Although levels of MMAE and DM1-containing catabolites released after administration of brentuximab vedotin and ado-trastuzumab emtansine are in the nanomolar range, 19, 49, 53 CYP3A inhibitory Ki values for these unconjugated molecules estimated from in vitro assays are in the micromolar range. 42, 54 These observations are consistent with a clinical study evaluating potential CYP3A-mediated DDIs of brentuximab vedotin in patients with CD30-positive hematologic malignancies, where MMAE was found to be neither an inducer nor an inhibitor of CYP3A when brentuximab vedotin was administered at the recommended dose of 1.8 mg/kg. 49 The investigators also evaluated the effect of ketoconazole (strong CYP3A inhibitor) and rifampin (strong CYP3A inducer) on MMAE exposure. MMAE area under the curve increased 34% with ketoconazole and decreased 46% with rifampin. Although the impact on clinical safety with the former is not known, lowering exposures from induction may minimize the safety risks related to payload exposure. In addition to CYP3A modulation, cytotoxics are often substrates of and may be inhibited by P-glycoprotein. No dedicated renal impairment study was conducted, but the effect of renal impairment was evaluated as part of a population PK analysis. A postmarketing evaluation of hepatic impairment was requested. Results: Compared with patients with normal renal function, MMAE exposure increased ß1.9-fold in patients with severe renal impairment (CrCl < 30 mL/min); compared with patients with normal hepatic function, MMAE exposure increased ß2.3-fold in patients with hepatic impairment (Child-Pugh A, B, or C). According to the package insert, patients with severe renal impairment and with hepatic impairment should be closely monitored for adverse reactions.
Results: Mild (CrCl = 60 to 89 mL/min) and moderate (CrCl = 30 to 59 mL/min) renal impairment did not have a meaningful effect on T-DM1 PK compared with normal renal function (CrCl ࣙ 90 mL/min).
Drug-drug interactions
Evaluated the CYP3A-mediated drug-drug interaction potential of brentuximab vedotin in an open-label, nonrandomized, parallel arm, 1-sequence crossover study in patients.
No formal clinical studies have been conducted. Results are based on in vitro studies.
Results: Brentuximab vedotin and resultant MMAE levels did not affect exposure to midazolam, a CYP3A probe substrate; rifampin, a potent CYP3A4 inducer, decreased MMAE exposure by ß46%; ketoconazole, a potent CYP3A4 inhibitor, increased MMAE exposure by ß34%. According to the package insert, patients also taking strong CYP3A4 inhibitors or P-glycoprotein inhibitors should be closely monitored for adverse reactions.
Results: According to the package insert, concomitant use of strong CYP3A4 inhibitors should be avoided because of the potential for an increase in DM1 exposure and toxicity; however, if patients are taking a strong CYP3A inhibitor, they should be closely monitored for adverse reactions.
QT/QTc interval prolongation
Evaluated the effect of brentuximab vedotin on cardiac ventricular repolarization in an open-label, single-arm study in patients.
Evaluated the effect of T-DM1 on cardiac ventricular repolarization in an open-label, single-arm study in patients.

Results:
The change from baseline in QTcF interval was <10 milliseconds at each point; using cycle 1 data, there was no significant positive or negative linear relationship between plasma MMAE concentrations and change in QTcF from baseline.
No large changes in the mean QT interval (ie, >20 milliseconds) were detected.
Population pharmacokinetics
Conducted separate analyses for brentuximab vedotin, total antibody, and MMAE.
Conducted separate analyses for T-DM1, total antibody, and DM1. Results: Sex, age, race, and ADA did not have a meaningful effect on the PK of brentuximab vedotin.
Results: Statistically significant covariates for T-DM1 PK parameters included sum of the longest diameter of target lesions by RECIST criteria, albumin, HER2 extracellular domain concentration, baseline trastuzumab concentration, AST, and body weight. Exposure-response Conducted E-R analyses for efficacy and safety end points using brentuximab vedotin and MMAE concentrations.
Conducted E-R analyses for efficacy and safety end points using T-DM1 concentration. Results: The probability of ORR increased with increasing brentuximab vedotin trough concentration, but decreased with increasing MMAE concentration; the probability of grade 2+ peripheral neuropathy increased with increasing average steady-state brentuximab vedotin trough concentration, but stayed flat with increasing average steady-state MMAE trough concentration; the probability of grade 3 or 4 neutropenia increased with increasing average steady-state brentuximab vedotin trough concentration, but showed a decreasing trend with increasing average steady-state MMAE trough concentration.
Results: After accounting for baseline risk factors, increases in T-DM1 exposure were related with better efficacy (OS, PFS, and ORR); an inverse trend for grade 3 or worse hepatotoxicity was identified, but no significant relationships were identified for thrombocytopenia.
(Continued) Overall incidence of positive (1 or more postdose time points) ADA to T-DM1 was determined to be 5.3% in the studies included in the BLA with the assays used.
Results: Based on a population PK analysis, brentuximab vedotin clearance was 18% faster in cycles when patients had a positive ADA response; however, the increased clearance did not have an impact on the PK profile. According to the sponsor, ADA does not affect the PK and/or PD of brentuximab vedotin. Limited data exist for potential DDIs with mAbs in ADCs, but the potential for DDIs is expected to be low, similar to that for other protein-based therapeutics. Antibodies are not typically metabolized by CYP450 and UDP-glucuronosyltransferase enzymes, 55 so coadministered small-molecule drugs are unlikely to affect antibody exposure, and mAb should not directly impact clearance pathways for small-molecule therapeutics. 56 However, other, less-direct interactions between mAb and coadministered small molecules may occur. 57 For instance, the immunomodulatory properties of an antibody (especially proinflammatory cytokine release) may influence CYP expression with a consequential impact on the clearance of coadministered drugs. 58, 59 Alternatively, mAb distribution may change if a concomitant medication affects TMDD.
Results
Physiologically based pharmacokinetic (PBPK) models that map drug movements in the body can also guide ADC development by predicting DDI risk. 60 As the use of PBPK modeling has become increasingly accepted and used to support regulatory submissions, both the FDA and the EMA have run workshops discussing the utility and limitations of PBPK modeling. 61 Validated PBPK models also build high confidence in prospective DDI predictions. 62 As stated elsewhere in this review, the large molecular size, poor membrane permeability, and mixture of DAR moieties make quantifying ADC distribution and elimination more complicated than other therapeutic agents, and PBPK modeling can help to predict tissue concentrations and disposition of these molecules in organs throughout the body. 63 
Immunogenicity Assessment
The development of antidrug antibodies (ADAs) may affect ADC safety and efficacy, with possible effects including hypersensitivity reactions, immune recognition of self-proteins, and alterations to drug exposure and activity if the ADAs are neutralizing. 64 With ADCs, ADAs may develop against the mAb, linker, or payload. The risk of developing ADAs depends on many product-, patient-, and disease-related factors and is likely influenced by patient immunological status. [64] [65] [66] Current regulatory guidelines for assessment of immunogenicity of therapeutic proteins can be applied to ADCs. 65, 66 A multitiered strategy for immunogenicity assessment is recommended, starting with screening assays to identify ADA-positive samples and patients, followed by confirming the presence of ADA, procedures to characterize antibody domain specificity, and functional assays to investigate the neutralizing capacity of the ADA. Finally, the relationship between ADA formation and PK, safety, and efficacy should be assessed. Making cross-study comparisons confusing, immunogenicity data are highly influenced by assay sensitivity/specificity, sample handling, timing of sample collection, drug interference, concomitant medications, and underlying disease.
ADCs currently in development for oncology indications may cause myelosuppression, which limits ADA formation, affecting their disposition and biological activity. A survey of published immunogenicity data for 9 ADCs found low ADA incidence (0% to 2.6%) for the 6 ADCs with data derived primarily from phase 1 studies. 64 However, these data may underestimate the true incidence of ADAs to these ADCs, because treatment duration and number of doses administered are relatively low in these early-phase studies. The incidence of ADAs for gemtuzumab ozogamicin (now withdrawn from the US market) was 1.1% among 182 tested patients. 64, 67 Among 156 patients treated with brentuximab vedotin, approximately 7% developed persistent ADAs, and 30% developed transiently positive ADAs; 36 of 58 patients tested for the presence of neutralizing antibodies (62%) had 1 or more positive samples. 68, 69 Based on population PK analysis, brentuximab vedotin clearance was 18% higher in ADApositive patients, but data simulations suggested this increase was not clinically meaningful. 69 So far the number of patients tested for the presence of ADAs is relatively small, and the effect of ADAs on the efficacy and safety of brentuximab vedotin is not evident. 68 However, patients positive for neutralizing ADAs had a higher incidence of infusion-related reactions (27%) than the overall study population (14%) without affecting ORR or the incidence of neuropathy, neutropenia, or thrombocytopenia. 69 Among 836 patients treated with ado-trastuzumab emtansine, 44 patients (5.3%) tested positive for ADAs at 1 or more time points after starting treatment. 47 The ADAs were not assessed for neutralizing activity, and their clinical significance is unknown. One explanation for the higher observed incidence of ADAs with brentuximab vedotin compared with other ADCs is that the former agent contains a chimeric rather than humanized mAb; the ADAs were directed against the mAb component of brentuximab vedotin in all patients with transiently or persistently positive antibodies. 68 Population PK and E-R Assessment Population PK analyses investigate reasons for variable drug exposure and guide dose adjustments within specific patient groups to ensure adequate exposure for efficacy while preserving safety. E-R relationships are similarly key to informing dosing recommendations. Both analyses are important for ADCs because of their often narrow therapeutic window and associated need for an optimal dosing regimen, and are complicated by the molecular composition of ADCs, requiring a comprehensive understanding of the particular analytes driving efficacy and safety.
Population PK analyses for brentuximab vedotin showed that sex, age, and race had no meaningful effects on PK, although body weight was a clinically and statistically important covariate, supporting weight-based dosing. 68 ,69 E-R analyses used ADC and MMAE concentrations, as total antibody levels were closely correlated with ADC. 69 The probability of response increased with increasing ADC C trough levels, but decreased with increasing MMAE concentration; the latter observation might be explained by MMAE failing to reach the tumor. 69 Safety E-R analyses considered the most frequent adverse events associated with brentuximab vedotin treatment in clinical trials, namely, peripheral neuropathy and neutropenia. The probability of peripheral neuropathy and neutropenia increased with greater ADC exposure, but remained flat or decreased with increasing MMAE levels; there was no clear E-R relationship with thrombocytopenia. 69 Ado-trastuzumab emtansine PK studies suggest intact ADC (referred to here as ado-trastuzumab emtansine conjugate) is the predominant analyte in plasma, with only low concentrations of DM1. 70 Population PK analysis identified several statistically significant covariates for clearance, including the sum of the longest diameter of target lesions by Response Evaluation Criteria In Solid Tumors version 1.1, albumin, HER2 extracellular domain concentrations, baseline trastuzumab concentrations, aspartate aminotransferase (AST), and body weight. 30, 71, 72 Albumin is believed to be related to ADC exposure because it is a marker of disease state, in which lower levels of albumin identify patients who clear the ADCs faster than patients with normal albumin levels. 73 However, the effect of these statistically significant covariates on ado-trastuzumab emtansine conjugate exposure was minimal and considered unlikely to be clinically relevant. E-R analysis showed that increased ado-trastuzumab emtansine conjugate exposure is related to improved efficacy with respect to both OS and PFS (co-primary end points of the phase 3 trial), as well as ORR. 74 The association between improved OS and PFS and increased ado-trastuzumab emtansine conjugate exposure held true in a Cox proportional hazards regression analysis, excluding the possibility of confounding by other covariates. Analysis of the relationship between ado-trastuzumab emtansine conjugate exposure and safety identified an inverse trend for increased AST or alanine aminotransferase and no significant relationship for thrombocytopenia; these were the most common toxicities leading to dose adjustments in the phase 3 trial. 74 The rate of dose adjustment was similar across exposure quartiles. The incidence of all grade ࣙ 3 adverse events combined was numerically higher in patients with low exposure (less than median C min , cycle 1, day 21) than with high exposure (greater than median C min , cycle 1, day 21). It is unclear if these potential trends are clinically meaningful. Another study used a semimechanistic PK/PD model to predict that the platelet nadir following adotrastuzumab emtansine 3.6 mg/kg every 3 weeks would occur after the first dose, thus supporting this as a tolerable dose requiring minimal dose delays or dose reductions for thrombocytopenia. 75 Application of Quantitative Systems Pharmacology Modeling Quantitative systems pharmacology modeling was previously used for ADC design optimization, 76, 77 prediction of tumor ADC concentrations, and increasing the understanding of intracellular ADC activation in preclinical tumor models. This information was then used to guide dose selection 78, 79 and translate data from preclinical species to humans to predict clinically efficacious doses. 80, 81 A multiscale, mechanism-based PK/PD model was built and validated using published brentuximab vedotin experimental data. 80 This model integrated all relevant preclinical measurements to de-velop a PK/PD model that predicted tumor payload concentrations in xenograft mice. PK parameters were then determined in patients and integrated with translated mouse parameters to predict clinical response, as assessed by PFS and complete response rates; model predictions were comparable with clinical observations. In another study, an optimized PD model describing xenograft tumor growth inhibition data translated adotrastuzumab emtansine efficacy from mice to patients. 81 The translational strategy was then applied to predict clinically efficacious FIH doses of a novel ADC.
As more clinical data become available, the scope of these quantitative systems pharmacology models can be extended to evaluate and optimize new dosing regimens including combination therapy, to optimize biomarker analyses, and to extrapolate findings from one tumor type to another.
Areas for Further Discussion and Consideration
The presence of multiple analytes after dosing is a critical factor contributing to the complexity of clinical pharmacology assessments for ADCs. The accepted consensus is that measurement of total antibody, conjugate, and unconjugated payload is sufficient to characterize the PK/PD of an ADC. 23, 38 Although measurement of these analytes may be sufficient, the contribution of each analyte to efficacy and toxicity is not always clear and may require further investigation to understand E-R relationships.
The above complexities help to explain the failure to establish clear E-R relationships between the most common toxicities observed with brentuximab vedotin and MMAE, and the lack of a convincing E-R safety relationship for ado-trastuzumab emtansine, despite in each case selecting a dose based on the MTD. 69, 74 Adotrastuzumab emtansine E-R analyses may be limited by using data from only one (pivotal) trial or a single dose; both disease state and PK may result in confounding clinical outcomes. International Conference on Harmonisation guidelines supported by a recent FDA guidance highlight the importance of study design, examination during early drug development, and using multiple doses when determining E-R relationships. 82, 83 Given the potential value of E-R analyses in guiding clinical development, these guidelines should be carefully considered for new ADCs.
The determination of biologically relevant analytes may be limited by the lack of a sufficiently sensitive and specific assay. Measuring payload may prove challenging with the development of more potent payloads; next-generation chemotypes such as pyrrolobenzodiazepine dimers have activity at subpicomolar concentrations, 84 with ADC doses in the microgram per kilogram range. 85 Similarly, our understanding of ADC immunogenicity is limited by assay limitations, with interpretations affected by assay sensitivity and specificity, drug interference, and sample handling and timing. Although data suggest little impact of immunogenicity on ADC function, variations in current assay methods, along with confounding factors such as the underlying disease, patient immunological status, and the general paucity of data make it difficult to draw firm conclusions. Undetected ADAs could even account for decreased ADC efficacy in some patients. Adherence by the industry to the relatively recent guidelines introduced by the FDA and the EMA on assessment of immunogenicity to therapeutic proteins may improve both data quantity and data quality for ADCs currently in development. 65, 66 With only 3 marketed ADCs to date, clinical experience is limited, and it is difficult to extrapolate from published data when considering new ADC development. However, utilization of prior clinical development experience with a particular payload/linker is crucial in customizing clinical development and clinical pharmacology strategies for newer ADCs, which can be adapted as scientific advances and regulatory understanding grows. Prior clinical development experience with a payload/linker similar to the new ADC can provide a framework to optimize clinical pharmacology assessments (eg, DDI and QTc).
Given the structural composition of ADCs, different ADC analytes might contribute differently to exposureefficacy and exposure-safety analyses. For example, DDI studies typically focus on the payload, yet, as previously discussed, the mAb may be responsible for indirect DDIs with coadministered drugs, particularly when proinflammatory cytokine release is induced. Therefore, the ADC mAb portion should be considered when assessing DDIs. It may also be appropriate to consider the impact of any theoretical activity related to the mAb mechanism of action when developing the clinical pharmacology strategy for ADCs, as the ADC mAb (when IgG1 isotype is used) may contribute antitumor activity in addition to the cytotoxic payload in the form of anti-ADCC and CDC. In one example, however, isotype did not seem to correlate with efficacy among anti-CD70−MMAF conjugates with IgG1, IgG1v lacking Fcγ R binding, and IgG2 isotypes. 86 An important area for further development is identifying suitable predictive and prognostic biomarkers for ADC response. As shown by ado-trastuzumab emtansine, the most obvious candidate remains the target antigen. However, target antigen shedding may limit the amount of ADC reaching target tumor cells. 87 The principle was illustrated by the immunotoxin SS1P, which targets the tumor-associated antigen mesothelin; reducing mesothelin shedding significantly improved in vitro SS1P cytotoxicity. 88, 89 In cases in which the level of tumor antigen shedding varies between individual patients, shed antigen may serve as a potential predictive marker of response.
What's New for ADCs?
A major focus for ADC development is developing homogeneous molecules with consistent DARs. Sitespecific conjugation technologies decrease heterogeneity with tighter control over DAR, more predictable manufacturing, and ultimately a better therapeutic window. These methods involve engineering reactive molecules to specific locations on the antibody, allowing for greater control of DAR. Multiple site-specific strategies are being used, including inserting exogenous cysteine residues with selective reactivity, adding unnatural amino acids, and enzymatic/chemoenzymatic conjugation. 90 Tub-tag labeling is a novel approach for the site-specific modification of antibodies that combines the addition of unnatural amino acids with the recognition motif for tubulin tyrosine ligase. 91 When recombinantly fused to an antibody, the tub-tag motif directs tubulin tyrosine ligase-mediated attachment with efficiencies up to 99% in vitro and is compatible with a broad range of established conjugation chemistries, including unnatural tyrosine derivatives that carry uniquely reactive groups for chemoselective conjugation such as strain-promoted alkyne azide cycloadditions. 92 Investigations examining the functional impact of adding a human-derived peptide to therapeutic antibodies are ongoing. Commercially available and self-labeling SNAP-tag technology, in which a 182-residue polypeptide tag covalently links proteins of interest to ligands, 93 has also been used to generate homogeneous ADCs, including novel recombinant ADCs designed to kill breast cancer cells. 94 To aid novel ADC development, initiatives to create ADCs more efficiently have begun. Antibody derivatives including single-chain fragment variable (scFv) regions were recently used in ADC development instead of mAbs because they are easier to modify and produce. 94, 95 These scFv-based ADCs also achieve greater tissue/tumor penetration than ADCs based off full-length mAbs. 94, 95 With the aim of improving ADC efficacy, new ADC technology adds a highly hydrophilic and polyvalent Fleximer polymer to overcome the limitations of direct drug-antibody conjugation by permitting high drug loading with a variety of payloads, without compromising the physicochemical and PK properties of the ADC. 96 Research suggests ADCs may be synergistic with immune checkpoint inhibitors, providing a strong rationale for exploring these combination strategies. 97, 98 Müller et al 97 recently showed that dolastatins (the family of microtubule inhibitors from which brentuximab vedotin, MMAE, is derived) combined with immune checkpoint inhibitors show synergistic antitumor activity and promote tumor destruction. Furthermore, ADCs coupled to MMAE induce dendritic cell (DC) homing in murine models, maturation of human DCs in lymphoma cell-DC co-cultures, and activation of T and B cells in patients, suggesting augmentation of tumor-specific immunity. Another study showed combined treatment with ado-trastuzumab emtansine and cytotoxic T-lymphocyte antigen 4 plus programmed death 1 immune checkpoint inhibitors caused tumor rejection in a HER2-expressing orthotopic tumor model, triggering innate and adaptive immunity. 98 Preliminary data from an ongoing phase 1/2 clinical trial demonstrated that treatment with brentuximab vedotin plus nivolumab (anti-programmed death 1) in patients with relapsed or refractory Hodgkin's lymphoma resulted in 90% ORR and an acceptable safety profile. 99 ADCs are also being combined with other drugs, including brentuximab vedotin with modified doxorubicin, vinblastine, and dacarbazine and ado-trastuzumab emtansine with phosphoinositide 3-kinase or tyrosine kinase inhibitors.
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Conclusion
ADCs are an emerging class of anticancer treatment agents that combine the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. Clinical validation of this concept was demonstrated with the recent approvals of 2 agents, brentuximab vedotin and ado-trastuzumab emtansine, which provided a basic understanding of the clinical pharmacology and pharmacometric approaches likely to support future ADC clinical development and regulatory approval. These approaches will continually evolve, especially in the context of supporting the clinical development of combination approaches of ADCs with other agents. Given the structural composition and pharmacological complexity, clinical pharmacology and pharmacometrics have a critical role in the development of this class of compounds. The success of ADCs in part will depend on our ability to overcome the developmental challenges discussed above, especially by identifying predictive biomarkers for assessing response and patient selection and developing clear strategies to address optimal dosing and scheduling of ADCs.
